Human CD40 Ligand/TNFSF5 DuoSet ELISA, 15 Plate

• Reactivity: Hu
• Applications: ELISA
• Conjugate: Biotin

Human CD40 Ligand/TNFSF5 DuoSet ELISA, 15 Plate Summary

• Assay Type: Solid Phase Sandwich ELISA
• Inter-Assay: See PDF Datasheet for details
• Intra-Assay: See PDF Datasheet for details
• Spike Recovery: See PDF Datasheet for details
• Sample Volume: See PDF Datasheet for details
• Gene: CD40LG

Applications/Dilutions

• Dilutions:
  • ELISA
• Application Notes: No significant interference observed with available related molecules.

Packaging, Storage & Formulations

• Storage: Store the unopened product at 2 - 8 °C. Do not use past expiration date.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Human CD40 Ligand/TNFSF5 DuoSet ELISA, 15 Plate

• CD154 antigen
• CD154
• CD40 antigen ligand
• CD40 Ligand
• CD40L
• CD40-L
• CD40LG
• CD40LIGM
• gp39
• hCD40L
• HIGM1
• T-B cell-activating molecule
• T-BAM
• T-cell antigen Gp39
• TNF-related activation protein
• TNFSF5
• TNFSF5IMD3
• TRAP
• TRAPtumor necrosis factor (ligand) superfamily, member 5 (hyper-IgM syndrome)
• tumor necrosis factor (ligand) superfamily member 5
• Tumor necrosis factor ligand superfamily member 5

Background

CD40 Ligand, also known as TNFSF5, CD154, TRAP, and gp39, is a trimeric protein that is expressed in transmembrane and soluble forms. It is expressed by many immune cell types as well as by endothelial and smooth muscle cells of the vasculature. It binds to CD40 on antigen presenting cells, platelets, and endothelial and epithelial cells, leading to enhanced B cell activation and T cell dependent humoral immune responses. CD40 Ligand dysregulation contributes to immune pathology in AIDS, atherosclerosis, atherothrombosis, and restenosis.

Publications for CD40 Ligand/TNFSF5 (DY617)(9)

Publications using DY617

• M Lenz, R Schönbauer, S Stojkovic, J Lee, C Gatterer, M Lichtenaue, V Paar, M Emich, M Fritzer-Sz, J Strametz-J, S Graf, M Sponder RANTES and CD40L under Conditions of Long-Term Physical Exercise: A Potential Link to Adaptive Immunity Oncogene, 2022-07-16;19(14):. 2022-07-16 [PMID: 35886510] (Human)
• L Song, X Zhao, R Chen, J Li, J Zhou, C Liu, P Zhou, Y Wang, Y Chen, H Zhao, H Yan Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes Cardiovascular Diabetology, 2022-05-20;21(1):80. 2022-05-20 [PMID: 35596184] (Human)
• RV da Costa S, LC Torres, EJA da Fonte, MJG Mello, JT de Oliveir, MC da Matta Analysis of physical activity and plasma levels of soluble CD40 and CD40L in older people with gastrointestinal tract cancer Experimental gerontology, 2022-01-11;0(0):111677. 2022-01-11 [PMID: 35031307] (Human)
• A Topf, M Mirna, N Bacher, V Paar, C Edlinger, LJ Motloch, S Gharibeh, M Bannehr, UC Hoppe, M Lichtenaue The Value of Fetuin-A as a Predictor to Identify Takotsubo Patients at Risk of Cardiovascular Events Journal of cardiovascular development and disease, 2021-10-05;8(10):. 2021-10-05 [PMID: 34677196] (Human)
• S Piantoni, F Regola, S Masneri, M Merletti, T Lowin, P Airò, A Tincani, F Franceschi, L Andreoli, G Pongratz Characterization of B- and T-Cell Compartment and B-Cell Related Factors Belonging to the TNF/TNFR Superfamily in Patients With Clinically Active Systemic Lupus Erythematosus: Baseline BAFF Serum Levels Are the Strongest Predictor of Response to Belimumab after Twelve Months of Therapy Frontiers in Pharmacology, 2021-05-21;12(0):666971. 2021-05-21 [PMID: 34093196] (Human)
• Serological signatures of clinical cure following successful treatment with sodium stibogluconate in Ethiopian visceral leishmaniasis Cytokine, 2016-12-08;91(0):6-9. 2016-12-08 [PMID: 27940090] (Human)
• Joseph W Jackson Novel Antiplatelet Activity of Minocycline Involves Inhibition of MLK3-p38 Mitogen Activated Protein Kinase Axis PLoS ONE, 2016-06-06;11(6):e0157115. 2016-06-06 [PMID: 27270236] (Human)
• Davidson D, Schifitto G, Maggirwar S Valproic acid inhibits the release of soluble CD40L induced by non-nucleoside reverse transcriptase inhibitors in human immunodeficiency virus infected individuals. PLoS ONE, 2013-03-28;8(3):e59950. 2013-03-28 [PMID: 23555843] (Human)
• Koutroubakis IE, Theodoropoulou A, Xidakis C, Sfiridaki A, Notas G, Kolios G, Kouroumalis EA Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol, 2004-11-01;16(11):1147-52. 2004-11-01 [PMID: 15489574] (Human)

FAQs for CD40 Ligand/TNFSF5 (DY617). (Showing 1 - 1 of 1 FAQs).

1. I am looking for paired ABs for use in detecting CD40L (rat) by ELISA. Do you have such a reagent(s) available?
   • Unfortunately we currently do not have any CD40 Ligand antibody pairs that have been validated in Rat. The only antibody pairs we offer for CD40L are validated in Human. I apologize for this inconvenience. If you would be interested in testing one of our products in Rat I'd like to invite you to participate in our Innovators Reward Program. Please contact us at innovators@novusbio.com with any questions regarding this program.

Bioinformatics

• Gene Symbol: CD40LG